|
1
|
Sun W, Lan X, Zhang H, Dong W, Wang Z, He
L, Zhang T and Liu S: Risk factors for central lymph node
metastasis in CN0 papillary thyroid carcinoma: A systematic review
and meta-analysis. PLoS One. 10:e01390212015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lundgren CI, Hall P, Dickman PW and
Zedenius J: Clinically significant prognostic factors for
differentiated thyroid carcinoma: A population-based, nested
case-control study. Cancer. 106:524–531. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lim H, Devesa SS, Sosa JA, Check D and
Kitahara CM: Trends in thyroid cancer incidence and mortality in
the United States, 1974–2013. JAMA. 317:1338–1348. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hundahl SA, Fleming ID, Fremgen AM and
Menck HR: A National Cancer Data Base report on 53,856 cases of
thyroid carcinoma treated in the U.S., 1985–1995 [see comments].
Cancer. 83:2638–2648. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mao Y and Xing M: Recent incidences and
differential trends of thyroid cancer in the USA. Endocr Relat
Cancer. 23:313–322. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sciuto R, Romano L, Rea S, Marandino F,
Sperduti I and Maini CL: Natural history and clinical outcome of
differentiated thyroid carcinoma: A retrospective analysis of 1503
patients treated at a single institution. Ann Oncol. 20:1728–1735.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Toniato A, Boschin I, Casara D, Mazzarotto
R, Rubello D and Pelizzo M: Papillary thyroid carcinoma: Factors
influencing recurrence and survival. Ann Surg Oncol. 15:1518–1522.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Grebe SK and Hay ID: Thyroid cancer nodal
metastases: Biologic significance and therapeutic considerations.
Surg Oncol Clin N Am. 5:43–63. 1996.PubMed/NCBI
|
|
9
|
Kouvaraki MA, Shapiro SE, Fornage BD,
Edeiken-Monro BS, Sherman SI, Vassilopoulou-Sellin R, Lee JE and
Evans DB: Role of preoperative ultrasonography in the surgical
management of patients with thyroid cancer. Surgery. 134:946–955.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mazzaferri EL and Kloos RT: Clinical
review 128: Current approaches to primary therapy for papillary and
follicular thyroid cancer. J Clin Endocrinol Metab. 86:1447–1463.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hay ID, Thompson GB, Grant CS, Bergstralh
EJ, Dvorak CE, Gorman CA, Maurer MS, McIver B, Mullan BP, Oberg AL,
et al: Papillary thyroid carcinoma managed at the Mayo Clinic
during six decades (1940–1999): Temporal trends in initial therapy
and long-term outcome in 2444 consecutively treated patients. World
J Surg. 26:879–885. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hobert O: Gene regulation by transcription
factors and microRNAs. Science. 319:1785–1786. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rosenfeld N, Aharonov R, Meiri E,
Rosenwald S, Spector Y, Zepeniuk M, Benjamin H, Shabes N, Tabak S,
Levy A, et al: MicroRNAs accurately identify cancer tissue origin.
Nat Biotechnol. 26:462–469. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yu L, Yang Y, Hou J, Zhai C, Song Y, Zhang
Z, Qiu L and Jia X: MicroRNA-144 affects radiotherapy sensitivity
by promoting proliferation, migration and invasion of breast cancer
cells. Oncol Rep. 34:1845–1852. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang SY, Lu ZM, Lin YF, Chen LS, Luo XN,
Song XH, Chen SH and Wu YL: miR-144-3p, a tumor suppressive
microRNA targeting ETS-1 in laryngeal squamous cell carcinoma.
Oncotarget. 7:11637–11650. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen S, Li P, Li J, Wang Y, Du Y, Chen X,
Zang W, Wang H, Chu H, Zhao G and Zhang G: MiR-144 inhibits
proliferation and induces apoptosis and autophagy in lung cancer
cells by targeting TIGAR. Cell Physiol Biochem. 35:997–1007. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cao T, Li H, Hu Y, Ma D and Cai X: miR-144
suppresses the proliferation and metastasis of hepatocellular
carcinoma by targeting E2F3. Tumour Biol. 35:10759–10764. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Guo Y, Ying L, Tian Y, Yang P, Zhu Y, Wang
Z, Qiu F and Lin J: miR-144 downregulation increases bladder cancer
cell proliferation by targeting EZH2 and regulating Wnt signaling.
FEBS J. 280:4531–4538. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Larionov A, Krause A and Miller W: A
standard curve based method for relative real time PCR data
processing. BMC Bioinformatics. 6:622005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC Cancer Staging Manual. 7th. Springer;
New York, NY: 2010
|
|
21
|
Liu C, Huang W and Lei Q: Regulation and
function of the TAZ transcription co-activator. Int J Biochem Mol
Biol. 2:247–256. 2011.PubMed/NCBI
|
|
22
|
de Cristofaro T, Di Palma T, Ferraro A,
Corrado A, Lucci V, Franco R, Fusco A and Zannini M: TAZ/WWTR1 is
overexpressed in papillary thyroid carcinoma. Eur J Cancer.
47:926–933. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen AY, Jemal A and Ward EM: Increasing
incidence of differentiated thyroid cancer in the United States,
1988–2005. Cancer. 115:3801–3807. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:pp. 2257–2261.
2006; View Article : Google Scholar : PubMed/NCBI
|
|
27
|
He H, Jazdzewski K, Li W, Liyanarachchi S,
Nagy R, Volinia S, Calin GA, Liu CG, Franssila K, Suster S, et al:
The role of microRNA genes in papillary thyroid carcinoma. Proc
Natl Acad Sci USA. 102:pp. 19075–19080. 2005; View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pallante P, Visone R, Ferracin M, Ferraro
A, Berlingieri MT, Troncone G, Chiappetta G, Liu CG, Santoro M,
Negrini M, et al: MicroRNA deregulation in human thyroid papillary
carcinomas. Endocr Relat Cancer. 13:497–508. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Santinon G, Pocaterra A and Dupont S:
Control of YAP/TAZ activity by metabolic and nutrient-sensing
pathways. Trends Cell Biol. 26:289–299. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hansen CG, Moroishi T and Guan KL: YAP and
TAZ: A nexus for Hippo signaling and beyond. Trends Cell Biol.
25:499–513. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Santucci M, Vignudelli T, Ferrari S, Mor
M, Scalvini L, Bolognesi ML, Uliassi E and Costi MP: The Hippo
pathway and YAP/TAZ-TEAD protein-protein interaction as targets for
regenerative medicine and cancer treatment. J Med Chem.
58:4857–4873. 2015. View Article : Google Scholar : PubMed/NCBI
|
